| Code | CSB-RA868278MB7HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of risankizumab-rzaa, targeting IL23A (IL-23 p19)—the IL-23–specific subunit of the heterodimeric cytokine IL-23 (p19 + p40). IL-23 is a central driver of the IL-23/Th17 axis, supporting maintenance of Th17 responses and downstream production of inflammatory mediators (notably IL-17/IL-22) that contribute to chronic immune inflammation, including the pathobiology of psoriatic disease.
Risankizumab-rzaa is a humanized IgG1 monoclonal antibody that selectively binds the p19 subunit of IL-23 and inhibits IL-23 interaction with the IL-23 receptor, thereby suppressing downstream inflammatory cytokine/chemokine programs associated with IL-23 signaling. This biosimilar enables researchers to investigate IL-23 pathway biology and pharmacologic neutralization effects in controlled experimental systems—supporting assay development (e.g., IL-23 blockade readouts), mechanistic studies on Th17-linked inflammation, and comparative benchmarking in disease-relevant models (e.g., plaque psoriasis, PsA, and IBD-related inflammation).
There are currently no reviews for this product.